Progress in development of bivalent vaccines against influenza A virus and SARS-CoV-2
10.3760/cma.j.cn112309-20230505-00116
- VernacularTitle:新型冠状病毒和甲型流感病毒双价疫苗研究进展
- Author:
Xiaoyan GUO
1
;
Chengcheng ZHAI
;
Jun WANG
Author Information
1. 内蒙古医科大学基础医学院，呼和浩特 010110
- Keywords:
SARS-CoV-2;
Influenza A virus;
Bivalent vaccine;
Immunoprotection
- From:
Chinese Journal of Microbiology and Immunology
2023;43(12):986-992
- CountryChina
- Language:Chinese
-
Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants continue to spread around the world, posing a great threat to global economic and public health. Influenza A virus, a major cause of influenza, has a wide host range and evolves rapidly. Influenza pandemics, which occur every 20 to 40 years, annual seasonal influenza epidemics, severe influenza and animal influenza viruses are all serious threats to public health. Clinical manifestations of infections caused by the two pathogens are very similar. It is of great significance to develop an effective bivalent vaccine for controlling alternating epidemics or co-infection of the two pathogens. This article reviewed the progress in the development of bivalent vaccines against SARS-CoV-2 and influenza A virus based on different platforms.
